2017 | 2016 | 2015 | 2014 | 2013 2012

2014

Cotelle P.
2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), Novel Inhibitors of HIV Integrase with a High Barrier to Resistance.
5th International Conference on Retroviral Integration, Asilomar Grove, California, (25/10/14)
invitation

Cotelle P.
Drug Discovery of Novel Inhibitors of HIV Integrase with a High Barrier to Resistance.
Univ of Toledo (Ohio, USA) (Toledo, 23/10/14)
invitation

Lebegue N.
Ciblage thérapeutique des interactions protéine-protéine.
Formation continue INSERM, Cap Hornu, St Valérie /somme (3-4 / 04 / 2014). invitation

 

Lebegue N, Renault N, Melnyk P, Van Seuningen I.
Ciblage thérapeutique du complexe oncogénique MUC4-ErbB2 par l'élaboration de molécules synthétiques visant les domaines EGF de MUC4.
Institut National du Cancer, Paris (09/ 2014).

 

Melnyk P.
Nouvelles approches thérapeutiques de la maladie d’Alzheimer.
XXIè Journées AECCPCM (Montpellier, 5-6 / 06 / 2014) invitation

 

Melnyk P.
Des ligands sigma-1 pour le traitement de maladies neurodégénératives : conception, synthèse et évaluation pharmacologique.
Univ Strasbourg (Strasbourg, 26 / 09 / 14) invitation

 

Melnyk P, Carato P, Toussaint M, Donnier-Maréchal M.
Fused Isoquinoline-Hydantoin as a Powerful Scaffold for the Design of Selective Sigma-1 Ligands.
BIT’s 5th Annual International of Medichem-2014 (Suzhou-China,18-20 / 11 /2014) invitation

 

Moas-Héloire V, Renault N, Chavatte P, Furman C, Blum D, Lopes VL, Melnyk P, Agouridas L.
Adenosine A2a receptor blockade protects against neurodegenerative diseases.
RECOB15 (Aussois, 23-27 / 03 / 2014)

 

Moas-Héloire V, Renault N, Batalha VL, Chavatte P, Yous S, Buée L, Blum D, Lopez LV, Buée L, Agouridas L, Melnyk P.
Targeting A2A receptor to treat neurodegenerative diseases: design, synthesis and evaluation of potential antagonists.
Purines2014 (Bonn, 23-27 / 07 / 2014)